Literature DB >> 19328668

Adoptive T cell therapy of cancer.

Ton N M Schumacher1, Nicholas P Restifo.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19328668      PMCID： PMC2693351          DOI： 10.1016/j.coi.2009.03.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


× No keyword cloud information.
  14 in total

1.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

Review 2.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

5.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

Review 6.  Antigen choice in adoptive T-cell therapy of cancer.

Authors:  Rienk Offringa
Journal:  Curr Opin Immunol       Date:  2009-03-16       Impact factor: 7.486

Review 7.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

Review 8.  T-cell-receptor gene therapy.

Authors:  Ton N M Schumacher
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

Review 9.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

10.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Authors:  Z Eshhar; T Waks; G Gross; D G Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205
View more
  14 in total

1.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

2.  Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.

Authors:  Claude Carnaud; Véronique Bachy
Journal:  Prion       Date:  2010-04-04       Impact factor: 3.931

3.  Selective expansion and enhanced anti-tumor effect of antigen-specific CD4(+) T cells by retrovirus-mediated IL-15 expression.

Authors:  Jizhou Lv; Ning Tao; Hao Wu; Xiaoman Liu; Xia Xu; Yingxin Xu; Zhihai Qin
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

Review 4.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

5.  Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma.

Authors:  Yung-Chang Lin; Chen-Yu Hsu; Sheng-Kai Huang; Yun-Han Fan; Chien-Hao Huang; Chan-Keng Yang; Wan-Ting Su; Po-Chia Chang; Avijit Dutta; Yu-Jen Liu; Ching-Tai Huang; Tse-Ching Chen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2018-09-19       Impact factor: 8.110

6.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

7.  IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Authors:  Mary Zimmerman; Dafeng Yang; Xiaolin Hu; Feiyan Liu; Nagendra Singh; Darren Browning; Vadivel Ganapathy; Phillip Chandler; Divaker Choubey; Scott I Abrams; Kebin Liu
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

Review 8.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

Review 9.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

10.  Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes.

Authors:  S D Soysal; S Muenst; J Kan-Mitchell; E Huarte; X Zhang; I Wilkinson-Ryan; T Fleming; V Tiriveedhi; T Mohanakumar; L Li; J Herndon; D Oertli; S P Goedegebuure; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2014-09-12       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.